Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review
Journal of Diabetes Research · 2025
DOI: 10.1155/jdr/6278075 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Diabetes Research, 2025. Verfasst von Samuel Inshutiyimana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Ke…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Plant Extracts, Hypoglycemic Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2DM) refers to a chronic metabolic disorder that results from insulin resistance, leading to impaired insulin action and uncontrolled plasma glucose levels. Acalypha wilkesiana is among medicinal plants that are ethnobotanically used in the management of T2DM. However, there is a paucity of information on its antidiabetic potential. This review is aimed at providing a current understanding of the mechanism of action, potency, and safety of Acalypha wilkesiana in T2DM therapy.
Methods
A narrative review was thoroughly conducted by searching Google Scholar and PubMed databases using a predefined combination of keywords. All gathered articles were reviewed for the content regarding T2DM, Acalypha wilkesiana , mechanism of action, and safety. A total of 44 articles were considered in this review.
Results
Several experimental studies revealed that extracts of Acalypha wilkesiana inhibit α ‐glucosidase and α ‐amylase, which normally break down carbohydrates postprandially. Notably, the ethanolic root bark extracts of Acalypha wilkesiana have shown lower inhibitory concentrations compared to those of both the plant extracts in other solvents and the acarbose drug, emphasizing its greater potency. Additionally, the leaves of Acalypha wilkesiana have been reported to have no harmful effects on the red blood cells of diabetic rabbits and can even restore the alloxan‐induced impairment of pancreas and spleen cells.
Conclusion
Acalypha wilkesiana demonstrates antihyperglycemic activity and can reverse the dysfunction of critical organs. It promises advances in the development of antihyperglycemic agents which are more efficacious and safer than synthetic agents. However, clinical trials should be conducted to establish human‐tailored doses, ensuring an improved safety profile of the plant in the treatment of T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.
- Department of Pharmaceutical Chemistry, Pharmacology and Pharmacognosy, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.
- Department of Pharmacy, Faculty of Pharmacy, Universitas Borneo Lestari, Banjarbaru, Indonesia.
ORCID-Profile: Samuel Inshutiyimana, Patel Dineshbhai Yesh, Michael Matiop Aleu, Aibekhanya Nkosana Sebata, Kenfa Ajumesi, Norhayati
Zitieren
APA
Inshutiyimana, S., Yesh, P. D., Aleu, M. M., Sebata, A. N., Ajumesi, K., & Norhayati (2025). Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review. Journal of Diabetes Research. https://doi.org/10.1155/jdr/6278075
Vancouver
Inshutiyimana S, Yesh PD, Aleu MM, Sebata AN, Ajumesi K, Norhayati. Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review. Journal of Diabetes Research. 2025. doi:10.1155/jdr/6278075
BibTeX
@article{Inshutiyimana2025,
author = {Inshutiyimana, Samuel and Yesh, Patel Dineshbhai and Aleu, Michael Matiop and Sebata, Aibekhanya Nkosana and Ajumesi, Kenfa and Norhayati},
title = {Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review},
journal = {Journal of Diabetes Research},
year = {2025},
doi = {10.1155/jdr/6278075}
}
EUVIMED